Assignee
RUGEN HOLDINGS CAYMAN LTD
KY·11 granted patents·1 pending application·57 citations·filing 2015–2023
Top patents by PatentIndex Score
12 records- 0193US10294230B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2018·Granted May 21, 2019·9 cites·28 claims
- 0293US9567341B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS (CAYMAN) LTD·Filed 2015·Granted Feb 14, 2017·12 cites·17 claims
- 0391US9968610B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2017·Granted May 15, 2018·9 cites·17 claims
- 0490US11136328B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2020·Granted Oct 5, 2021·2 cites·20 claims
- 0589US10030026B2Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2015·Granted Jul 24, 2018·9 cites·20 claims
- 0686US10584127B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2016·Granted Mar 10, 2020·4 cites·27 claims
- 0786US10420768B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2018·Granted Sep 24, 2019·4 cites·10 claims
- 0885US10221182B23,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2016·Granted Mar 5, 2019·5 cites·19 claims
- 0982US11752155B2Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disordersRUGEN HOLDINGS CAYMAN LTD·Filed 2021·Granted Sep 12, 2023·1 cites·23 claims
- 1080US11000526B2Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disordersRUGEN HOLDINGS CAYMAN LTD·Filed 2017·Granted May 11, 2021·2 cites·25 claims
- 1175US12527799B2Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disordersRUGEN HOLDINGS CAYMAN LTD·Filed 2023·Granted Jan 20, 2026·0 cites·18 claims
- 1274US2022024937A13,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when RUGEN HOLDINGS CAYMAN LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →